Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin
| dc.contributor.author | Nicolaides, C. | en |
| dc.contributor.author | Giannakakis, T. | en |
| dc.contributor.author | Skarlos, D. | en |
| dc.contributor.author | Athanassiadis, A. | en |
| dc.contributor.author | Fountzilas, G. | en |
| dc.contributor.author | Damigos, D. | en |
| dc.contributor.author | Pavlidis, N. | en |
| dc.date.accessioned | 2015-11-24T19:04:01Z | |
| dc.date.available | 2015-11-24T19:04:01Z | |
| dc.identifier.issn | 0392-9078 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19954 | |
| dc.rights | Default Licence | - |
| dc.subject | 5-ht3 receptor antagonist | en |
| dc.subject | tropisetron | en |
| dc.subject | acute emesis | en |
| dc.subject | high dose epirubicin | en |
| dc.subject | antiemetic agents | en |
| dc.subject | induced emesis | en |
| dc.subject | ics 205-930 | en |
| dc.subject | chemotherapy | en |
| dc.subject | ondansetron | en |
| dc.subject | antagonist | en |
| dc.title | Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin | en |
| heal.abstract | Tropisetron is a novel selective antagonist of the type-3 serotonin (5-HT3) receptor, with proven efficacy in the control of emesis related to cancer treatment. Epirubicin in doses of >100 mg/m(2) has a high emetogenic potential. This study was designed to determine whether a single intravenous administration of tropisetron could prevent acute nausea and vomiting in patients treated with high dose: epirubicin. Forty chemotherapy naive breast cancer patients treated with epirubicin at a dose of 110 mg/m(2) on an outpatient basis were enrolled in the study. Tropisetron 5 mg i.v. was used as antiemetic prophylaxis. "On demand" treatment with tropisetron 5 mg p.os was used for the rescue of patients who failed on the initial iv dose. Complete control of acute nausea and vomiting had 62.5% (95% C.1, 47.2 - 77.8), partial control 15% (95% C.1, 3.8-26.2) and 22.5% (95% C.1. 9.3-35.7) insufficient control or failure. Headache was the most common adverse event reported in 3 patients (7.5%) and constipation in 2 patients (5%). Interestingly, patients with a negative experience of nausea and vomiting during pregnancy and those treated for metastatic disease, had a better control of chemotherapy-induced nausea and vomiting. In conclusion, a single 5 mg i.v. dose of tropisetron is safe and effective in preventing acute emesis in patients treated with high dose epirubicin. | en |
| heal.access | campus | - |
| heal.fullTextAvailability | TRUE | - |
| heal.identifier.secondary | <Go to ISI>://000073534200010 | - |
| heal.journalName | Journal of Experimental & Clinical Cancer Research | en |
| heal.journalType | peer-reviewed | - |
| heal.language | en | - |
| heal.publicationDate | 1998 | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.type | journalArticle | - |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.type.en | Journal article | en |
Αρχεία
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: